

Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form SC 13G

ACHILLION PHARMACEUTICALS INC
Form SC 13G
May 29, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

Achillion Pharmaceuticals, Inc.

(Name of Issuer)

Common Shares, \$0.001 par value

(Title of Class of Securities)

00448Q201

(CUSIP Number)

Camber Capital Management LLC, 101 Huntington Avenue, Boston, MA 02199,
617-717-6600

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

May 19, 2014

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 00448Q201

13G

Page 2 of 6 Pages

- 1. Names of Reporting Persons.
Camber Capital Management LLC
I.R.S. Identification Nos. of above persons (entities only)

42-1693587

- 2. Check the Appropriate Box If a Member of a Group

Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form SC 13G

(See Instructions)

(a)

(b)

3. SEC Use Only

4. Citizenship or Place of Organization

Camber Capital Management LLC -- Massachusetts

5. SOLE VOTING POWER

0 shares

6. SHARED VOTING POWER

5,700,000 shares

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH

7. SOLE DISPOSITIVE POWER

0 shares

8. SHARED DISPOSITIVE POWER

5,700,000 shares

9. Aggregate Amount Beneficially Owned by Each Reporting Person

Camber Capital Management LLC -- 5,700,000 shares

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)

11. Percent of Class Represented by Amount in Row (9)

Camber Capital Management LLC -- 5.89%

12. Type of Reporting Person (See Instructions)

Camber Capital Management LLC -- 00 (Limited Liability Company)

CUSIP No. 00448Q201

13G

Page 3 of 6 Pages

1. Names of Reporting Persons.

Stephen DuBois

I.R.S. Identification Nos. of above persons (entities only)

N/A

2. Check the Appropriate Box If a Member of a Group
(See Instructions)

(a)

(b)

3. SEC Use Only

Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form SC 13G

4. Citizenship or Place of Organization

Stephen DuBois -- United States

	5. SOLE VOTING POWER	0 shares
	6. SHARED VOTING POWER	5,700,000 shares
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7. SOLE DISPOSITIVE POWER	0 shares
	8. SHARED DISPOSITIVE POWER	5,700,000 shares

9. Aggregate Amount Beneficially Owned by Each Reporting Person

Stephen DuBois -- 5,700,000 shares

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)

11. Percent of Class Represented by Amount in Row (9)

Stephen DuBois -- 5.89%

12. Type of Reporting Person (See Instructions)

Stephen DuBois -- IN

CUSIP No. 00448Q201

13G

Page 4 of 6 Pages

Item 1.

- (a) Name of Issuer:
Achillion Pharmaceuticals, Inc.
- (b) Address of Issuer's Principal Executive Offices:
300 George Street, New Haven, CT 06511

Item 2.

- (a) Name of Person Filing:
Camber Capital Management LLC
Stephen DuBois
- (b) Address of the Principal Office or, if none, residence:
Camber Capital Management LLC
Stephen DuBois
101 Huntington Avenue
Suite 2550
Boston, MA 02199

Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form SC 13G

- (c) Citizenship:
Camber Capital Management -- Massachusetts
Stephen DuBois -- United States
- (d) Title of Class of Securities:
Common Shares, \$0.001 par value (the "Common Shares")
- (e) CUSIP Number:
00448Q201

Item 3. If this statement is filed pursuant to SS.240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) An investment adviser in accordance with S.240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with S.240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with S. 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) Group, in accordance with S.240.13d-1(b)(1)(ii)(J).

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: Camber Capital Management LLC -- 5,700,000
Stephen DuBois -- 5,700,000
- (b) Percent of class: Camber Capital Management LLC -- 5.89%
Stephen DuBois -- 5.89%

CUSIP No. 00448Q201

13G

Page 5 of 6 Pages

- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote
Camber Capital Management LLC -- 0
Stephen DuBois -- 0

Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form SC 13G

- (ii) Shared power to vote or to direct the vote
Camber Capital Management LLC -- 5,700,000
Stephen DuBois -- 5,700,000

- (iii) Sole power to dispose or to direct the disposition
of
Camber Capital Management LLC-- 0
Stephen DuBois -- 0.

- (iiii) Shared power to dispose or to direct the disposition
of
Camber Capital Management LLC-- 5,700,000
Stephen DuBois -- 5,700,000

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following | |.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Item 8. Identification and Classification of Members of the Group

Item 9. Notice of Dissolution of Group

Item 10. Certification

- (b) The following certification shall be included if the statement is filed pursuant to S.240.13d-1(c):

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

CAMBER CAPITAL MANAGEMENT LLC

By: /s/Sean George

Sean George

Chief Financial Officer

STEPHEN DUBOIS

By: /s/ Stephen DuBois

Stephen DuBois, individually

Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form SC 13G

This Joint Filing Agreement, dated May 29, 2014, is by and between Camber Capital Management LLC, a Massachusetts limited liability company, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G with respect to common shares, \$0.001 par value of Achillion Pharmaceuticals, Inc. beneficially owned by them from time to time. Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule. This Joint Filing Agreement may be terminated by any of the Filers upon one week's prior written notice or such lesser period of notice as the Filers may mutually agree.

Executed and delivered as of the date first above written.

CAMBER CAPITAL MANAGEMENT LLC

By: /s/ Sean George

Sean George

Chief Financial Officer

STEPHEN DUBOIS

By: /s/ Stephen DuBois

Stephen DuBois, individually